212141-54-3

Basic information

• Product Name: Vatalanib base
• Synonyms: N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)- 1-Phthalazinamine;1-PhthalazinaMine, N-(4-chlorophenyl)-4-(4-pyridinylMethyl)-;Vatalanib (PTK787) Dihydrochloride Base;Pynasunate, ZK222584, CGP-79787, PTK 787;(4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine;Vatalanib (free base);VATALANIB
• CAS NO: 212141-54-3
• Molecular Formula: C₂₀H₁₅ClN₄
• Molecular Weight: 346.81
• Product Categories: Antineoplastic
• Mol File: 212141-54-3.mol

Chemical Properties

• Melting Point: 209-212°
• Boiling Point: 587.8 °C at 760 mmHg
• Flash Point: 309.3 °C
• Appearance: /
• Density: 1.33 g/cm₃
• Vapor Pressure: 8.48E-14mmHg at 25°C
• Refractive Index: 1.711
• Storage Temp.: 2-8°C(protect from light)
• Solubility: ≥16.85 mg/mL in DMSO; ≥3.0125 mg/mL in EtOH with gentle warming and ultrasonic; ≥32.53 mg/mL in H2O with gentle warming and ultrasonic
• PKA: 5.46±0.10(Predicted)
• CAS DataBase Reference: Vatalanib base(CAS DataBase Reference)
• NIST Chemistry Reference: Vatalanib base(212141-54-3)
• EPA Substance Registry System: Vatalanib base(212141-54-3)

Safety Data

• Hazardous Substances Data: 212141-54-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Vatalanib base is used as an anti-viral agent for its ability to inhibit the activity of various tyrosine kinases, which play a crucial role in the replication and spread of viruses. By targeting these enzymes, Vatalanib base can potentially disrupt the viral life cycle and reduce the severity of viral infections.
Used in Oncology:
Vatalanib base is used as an anti-cancer agent, particularly in the treatment of solid tumors. It works by inhibiting the activity of multiple tyrosine kinases, such as VEGFR, PDGFR, and c-Kit, which are often overexpressed in cancer cells. This inhibition can lead to the suppression of tumor growth, angiogenesis, and metastasis, making it a promising candidate for cancer therapy.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of Vatalanib base, various drug delivery systems have been developed. These systems, which may include organic and metallic nanoparticles, aim to improve the delivery of Vatalanib base to target cells, reducing side effects and increasing therapeutic outcomes.

InChI:InChI=1/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)

Upstream product

• 106-47-8 4-chloro-aniline 
• 107558-48-5 5-(pyridin-4-yl)methyl-2H-phthalazin-1-one 
• 87-41-2 2-benzofuran-1(3H)-one 
• 67592-40-9 3-hydroxy-2-(pyridin-4-yl)-1H-inden-1-one 
• 54751-01-8 4-(bromomethyl)pyridine 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 106-39-8 bromochlorobenzene 
• 637-87-6 1-Chloro-4-iodobenzene 
• 91-15-6 phthalonitrile 

Downstream Products

• 300843-20-3 ZK 228354 
• 300843-29-2 1-(4-Chlor-anilino)-4-(pyridin-4-yl-fluormethyl)-phthalazine 

Relevant articles and documents

Simple preparation method of vatalanib

The invention provides a simple preparation method of vatalanib. The method comprises the following steps: carrying out a Grignard reaction on 4-halomethylpyridine (III) and metallic magnesium to prepare a corresponding Grignard reagent, carrying out addition on the Grignard reagent and phthalonitrile, condensing the obtained addition product and hydrazine hydrate to prepare 1-amino-4-(pyridin-4-yl)methylpyridazine (IV), and carrying out a substitution reaction on the 1-amino-4-(pyridin-4-yl)methylpyridazine (IV) and 4-halochlorobenzene (V) to obtain the vatalanib (II). The method of the invention has the advantages of small amount of generated wastewater, small toxicity of the raw materials, safety, environmental friendliness, and high safety of the prepared vatalanib; and the finally prepared product has a high purity and a high yield.

METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES

The invention relates to the use of certain phthalazines in the preparation of medicaments for the treatment of ocular neovascularization.

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

Method for delivering drugs to the retina

The invention relates to methods for the delivery of certain phthalazine derivatives to the retina(s) of a subject in need of treatment.

Ocular therapy

A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: wherein n is 0 to 2, R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl; and Z is unsubstituted or substituted pyridyl, an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom, or a salt thereof.

Method for treating ocular neovascular diseases

The invention relates to the use of certain phthalazines in the preparation of medicaments for the treatment of ocular neovascularization.

Method for treating ocular neovascular diseases

The invention relates to the use of certain phthalazines in the preparation of medicaments for the treatment of ocular neovascularization.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

The sprouting of new blood vessels, or angiogenesis, is necessary for any solid tumor to grow large enough to cause life-threatening disease. Vascular endothelial growth factor (VEGF) is one of the key promoters of tumor induced angiogenesis. VEGF receptors, the tyrosine kinases Flt-1 and KDR, are expressed on vascular endothelial cells and initiate angiogenesis upon activation by VEGF. 1-Anilino-(4-pyridylmethyl)-phthalazines, such as CGP 79787D (or PTK787/ZK222584), reversibly inhibit Flt-1 and KDR with IC50 values 50 = 34 nM). Modification of the 1-anilino moiety afforded derivatives with higher selectivity for the VEGF receptor tyrosine kinases Flt-1 and KDR compared to the related receptor tyrosine kinases PDGF-R and c-Kit. Since these 1-anilino-(4-pyridylmethyl)phthalazines are orally well absorbed, these compounds qualify for further profiling and as candidates for clinical evaluation.